{
  "abstract": "In a population-based cohort study by Razaz et al,1 risks of neurodevelopmental disorders in 2051 children of fathers taking valproate monotherapy during spermatogenesis were no different to those taking levetiracetam or lamotrigine. The authors demonstrate how this aligns with several other population-based studies cited2–4 and a systematic review.5 An international study in 91 917 men taking valproate found no difference in fertility compared to unexposed men with the same health conditions.6 These studies illustrate well-designed and conducted analyses of large datasets.",
  "authors": [
    {
      "affiliations": [
        "Epilepsy Initiative Group, Royal Free Hampstead NHS Trust, London, England, UK",
        "University College London Institute of Neurology, London, UK"
      ],
      "name": "Heather Angus-Leppan"
    }
  ],
  "title": "Is it time for the removal of valproate restrictions in men? Further evidence from a new study",
  "uid": "2499bb1f-3a5d-51de-936d-0bd876b76a40"
}